US · Healthcare · Biotechnology
EPS came in at -1.36 against a street estimate of -1.23 — a miss of 10.6%.
Analysts rate Arrowhead Pharmaceuticals Inc a buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $110.00.
CONFIDENT REDEMPLO approved for FCS; Phase III sHTG data shows 79-81% TG reduction and 78% pancreatitis risk cut. Priority review voucher acquired to accelerate launch. Multiple pipeline readouts expected by year-end. Q3 FY26 5-geography approved footprint; European reimbursement to proceed country-by-country starting Germany this month. Ex-U.S. revenue magnitude uncertain pending MFN/policy clarity. Analysts probed sNDA timing (CFO/CMO: pre-meeting + modules finalized by year-end), ARO-MAPT knockdown expectations (CMO: sticking 50-60%), and sHTG competitive positioning (CEO/VP Commerc: slow educational ramp, 1,500 specialist overlap with FCS). Management largely deflected detailed SHASTA safety data pending ESC embargo lift. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.86% |
| venBio Select Advisor LLC | 7.58% |
| FMR Inc | 5.14% |
| Vanguard Portfolio Management, LLC | 5.06% |
| State Street Corp | 4.60% |
| Vanguard Capital Management, LLC | 4.27% |
| Geode Capital Management, LLC | 3.03% |
| NORGES BANK | 2.76% |
| Document | Date |
|---|---|
| Quarterly report · Q3 FY2026 ARROWHEAD PHARMACEUTICALS, INC. – Q2 FY2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (9M 2026): $413.0 million vs. $573.0 million (9M 2025) – down 28 | 2026-08-04 |
| Results announced · Q4 FY2026 ARROWHEAD PHARMACEUTICALS FY2026 Q3 RESULTS SUMMARY HEADLINE NUMBERS • Revenue: $75.253 million (Q3 2026) vs. $27.767 million (Q3 2025) — 171% incre | 2026-08-04 |
| Board / officer change · Q3 FY2026 ARROWHEAD PHARMACEUTICALS, INC. - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Director Appointment: Dr. Matt Cohen, M.D., M.B.A., was appointed to the B | 2026-06-16 |
| Quarterly report · Q2 FY2026 ARROWHEAD PHARMACEUTICALS, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (6 months): $337.8 million (down 38% from $545.2 million in prior | 2026-05-07 |
| Results announced · Q3 FY2026 ARROWHEAD PHARMACEUTICALS – Q2 FISCAL 2026 RESULTS SUMMARY HEADLINE NUMBERS • Revenue: $73.7 million (Q2 2026) vs. $542.7 million (Q2 2025) – signif | 2026-05-07 |
| Shareholder vote results · Q2 FY2026 ARROWHEAD PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Shares Outstanding (Record Date): 140,010,690 common shares as of January 22, | 2026-03-20 |
| Quarterly report · Q1 FY2026 ARROWHEAD PHARMACEUTICALS, INC. - Q1 FY2026 SUMMARY HEADLINE NUMBERS • Revenue: $264.0 million in Q1 FY2026 vs. $2.5 million in Q1 FY2025 (105-fold | 2026-02-05 |
| Proxy statement · Q2 FY2026 ARROWHEAD PHARMACEUTICALS, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Elect Seven Directors: Vote FOR each of the | 2026-01-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA approves REDEMPLO for familial chylomicronemia syndrome treatment Arrowhead Pharmaceuticals announced FDA approval of REDEMPLO® (plozasiran) on November 18, 2025. REDEMPLO is a new drug designed to reduce triglycerides in adults with familial chylomicronem | 2025-11-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Arrowhead Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.